Pharming Group N.V [PHAR] vs Recursion [RXRX] Detailed Stock Comparison

Pharming Group N.V. - ADR

NASDAQ
Loading...

Recursion Pharmaceuticals Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Pharming Group N.V. - ADR wins in 14 metrics, Recursion Pharmaceuticals Inc. wins in 5 metrics, with 0 ties. Pharming Group N.V. - ADR appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Pharming Group N.V. - ADR Recursion Pharmaceuticals Inc. Better
P/E Ratio (TTM) 428.25 -2.44 Pharming Group N.V. - ADR
Price-to-Book Ratio 4.34 1.64 Recursion Pharmaceuticals Inc.
Debt-to-Equity Ratio 41.78 6.89 Recursion Pharmaceuticals Inc.
PEG Ratio 46.68 0.04 Recursion Pharmaceuticals Inc.
EV/EBITDA 309.61 -2.10 Pharming Group N.V. - ADR
Profit Margin (TTM) 0.76% 4.45% Recursion Pharmaceuticals Inc.
Operating Margin (TTM) 2.84% -328.80% Pharming Group N.V. - ADR
EBITDA Margin (TTM) 2.84% N/A N/A
Return on Equity 1.02% -59.54% Pharming Group N.V. - ADR
Return on Assets (TTM) 4.55% -27.72% Pharming Group N.V. - ADR
Free Cash Flow (TTM) $53.95M $-380.44M Pharming Group N.V. - ADR
1-Year Return 22.55% -14.11% Pharming Group N.V. - ADR
Price-to-Sales Ratio (TTM) 3.22 24.83 Pharming Group N.V. - ADR
Enterprise Value $12.27B $1.19B Pharming Group N.V. - ADR
EV/Revenue Ratio 32.61 15.88 Recursion Pharmaceuticals Inc.
Gross Profit Margin (TTM) 80.19% 59.62% Pharming Group N.V. - ADR
Revenue per Share (TTM) $5 $0 Pharming Group N.V. - ADR
Earnings per Share (Diluted) $0.04 $-1.44 Pharming Group N.V. - ADR
Beta (Stock Volatility) 0.12 1.01 Pharming Group N.V. - ADR
Short % of Float 0.02% 34.94% Pharming Group N.V. - ADR

Pharming Group N.V. - ADR vs Recursion Pharmaceuticals Inc. Stock Performance Analysis

Loading Price Chart...

PHAR
RXRX

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Pharming Group N.V. - ADR-0.33%-8.72%-25.32%-20.52%-22.58%-28.59%
Recursion Pharmaceuticals Inc.-3.88%9.46%-1.42%-1.98%-25.54%-17.38%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Pharming Group N.V. - ADR22.55%7.00%5.44%-16.68%-16.68%-16.68%
Recursion Pharmaceuticals Inc.-14.11%-56.38%-87.80%-88.53%-88.53%-88.53%

Performance & Financial Health Analysis: Pharming Group N.V. - ADR vs Recursion Pharmaceuticals Inc.

MetricPHARRXRX
Market Information
Market Cap i$1.24B$1.85B
Market Cap CategorySmall capSmall cap
10 Day Avg. Volume i13,62811,402,630
90 Day Avg. Volume i20,98912,390,473
Last Close$12.24$3.47
52 Week Range$9.53 - $21.34$2.77 - $7.18
% from 52W High-42.64%-51.67%
All-Time High$21.99 (Dec 21, 2020)$42.81 (Jul 12, 2021)
% from All-Time High-44.34%-91.89%
Growth Metrics
Quarterly Revenue Growth0.15%6.82%
Quarterly Earnings Growth0.86%6.84%
Financial Health
Profit Margin (TTM) i0.01%0.04%
Operating Margin (TTM) i0.03%-3.29%
Return on Equity (TTM) i0.01%-0.60%
Debt to Equity (MRQ) i41.786.89
Cash & Liquidity
Book Value per Share (MRQ)$3.95$2.14
Cash per Share (MRQ)$0.26$1.41
Operating Cash Flow (TTM) i$54.71M$-371,808,000
Levered Free Cash Flow (TTM) i$68.65M$-208,521,744
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Pharming Group N.V. - ADR vs Recursion Pharmaceuticals Inc.

MetricPHAR (Apr 21, 2026)RXRX (Apr 26, 2026)
Price Ratios
P/E Ratio (TTM) i428.25-2.44
Forward P/E i46.68-4.12
PEG Ratio i46.680.04
Price to Sales (TTM) i3.2224.83
Price to Book (MRQ) i4.341.64
Market Capitalization
Market Capitalization i$1.24B$1.85B
Enterprise Value i$12.27B$1.19B
Enterprise Value Metrics
Enterprise to Revenue i32.6115.88
Enterprise to EBITDA i309.61-2.10
Risk & Other Metrics
Beta i0.121.01
Book Value per Share (MRQ) i$3.95$2.14

Financial Statements Comparison: Pharming Group N.V. - ADR vs Recursion Pharmaceuticals Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricPHAR (2025)RXRX (2025)
Revenue/Sales i376.13M74.26M
Cost of Goods Sold i45.50M70.95M
COGS % of Revenue i12.1%95.6%
Gross Profit i330.63M3.30M
Gross Margin i87.9%4.4%
Research & Development i100.37M475.27M
Operating Income (EBIT) i20.88M-648.13M
Operating Margin i5.6%-872.8%
EBITDA i36.28M-559.38M
EBITDA Margin i9.6%-753.3%
Pre-Tax Income i12.85M-644.90M
Pre-Tax Income % of Revenue i3.4%-868.5%
Income Tax i10.31M-136,000
Income Tax % of Revenue i2.7%-0.2%
Net Income (Profit) i2.54M-644.76M
Profit Margin i0.7%-868.3%

Balance Sheet & Liquidity Metrics

MetricPHAR (2025)RXRX (2025)
Cash & Equivalents i145.31M743.29M
Total Current Assets i299.47M812.85M
Total Current Assets % of Revenue i79.6%1,094.7%
Total Current Liabilities i115.79M147.71M
Total Current Liabilities % of Revenue i30.8%198.9%
Long-Term Debt i107.07M56.21M
Long-Term Debt % of Revenue i28.5%75.7%
Total Shareholders Equity i277.10M1.13B
Retained Earnings i-272.98M-2.08B
Retained Earnings % of Revenue i-72.6%-2,795.7%
Property, Plant & Equipment i6.12M158.71M

Cash Flow Statement Comparison

MetricPHAR (2025)RXRX (2025)
Operating Cash Flow i47.47M-422.39M
Operating Cash Flow % of Revenue i12.6%-568.8%
Capital Expenditures iN/A-6.47M
Free Cash Flow i53.95M-380.44M
FCF Margin i14.3%-512.3%
Debt Repayment i-4.25M-8.43M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricPHARRXRX
Shares Short i12,882174.40M
Short Ratio i0.5414.00
Short % of Float i0.02%34.94%
Shares Outstanding i701.68M528.18M
Float Shares i690.78M510.29M
% Held by Insiders i0.00%2.85%
% Held by Institutions i0.20%64.60%
% Held by Public i99.80%32.55%

Dividend Analysis & Yield Comparison: Pharming Group N.V. - ADR vs Recursion Pharmaceuticals Inc.

MetricPHARRXRX
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A